The pathobiology of pulmonary hypertension: Lessons from experimental studies

Congenital Diseases in the Right Heart

Volumn , Issue , 2009, Pages 39-47

  Merklinger, Sandra ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651335247     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-378-1_5     Document Type: Chapter

References (108)

1. Rabinovitch, M., Pathology of Pulmonary Hypertension. Progress in Pediatric Cardiology, 2001. 12: P. 223-247
2. Rabinovitch, M., et al., Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation, 1978. 58(6): P. 1107-22
3. Meyrick, B. and L. Reid, Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol, 1980. 101(3): P. 527-42
4. Rabinovitch, M., Diseases of the Pulmonary Vasculature, in Comprehensive Cardiovascular Medicine, T. EJ, Editor. 1998, Lippincott-Raven Publishers: Philadelphia. p. 3001-3029
5. Heath, D. and J.E. Edwards, The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation, 1958. 18(4 Part 1): P. 533-47
6. Billingham, M.E., Histopathology of graft coronary disease. J Heart Lung Transplant, 1992. 11(3 Pt 2): P. S38-44
7. Ip, J.H., et al., Syndromes of accelerated atherosclerosis: Fole of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol, 1990. 15(7): P. 1667-87
8. Ross, R., The pathogenesis of atherosclerosis-an update. N Engl J Med, 1986. 314(8): P. 488-500
9. Rabinovitch, M., et al., Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest, 1986. 55(6): P. 632-53
10. Fuse, S. and T. Kamiya, Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation, 1994. 90(6): P. 2952-5
11. Christman, B.W., et al., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med, 1992. 327(2): P. 70-5
12. Resnick, N. and M.A. Gimbrone, Jr., Hemodynamic forces are complex regulators of endothelial gene expression. Faseb J, 1995. 9(10): P. 874-82
13. Topper, J.N., et al., Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase- 2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A, 1996. 93(19): P. 10417-22
14. Turner-Gomes, S.O., et al., Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg, 1992. 103(1): P. 87-97
15. Rabinovitch, M., et al., Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation, 1987. 76(5): P. 1043-52
16. Celermajer, D.S., S. Cullen, and J.E. Deanfield, Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation, 1993. 87(2): P. 440-6
17. Dinh Xuan, A.T., et al., Impairment of pulmonary endotheliumdependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol, 1990. 99(1): P. 9-10
18. Adatia, I. and S.G. Haworth, Circulating endothelin in children with congenital heart disease. Br Heart J, 1993. 69(3): P. 233-6
19. Yoshibayashi, M., et al., Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation, 1991. 84(6): P. 2280-5
20. Botney, M.D., et al., Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension. Am J Pathol, 1993. 143(1): P. 121-9
21. Prosser, I.W., et al., Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization. Am J Pathol, 1989. 135(6): P. 1073-88
22. Botney, M.D., et al., Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol, 1992. 140(2): P. 357-64
23. Plestina, R. and H.B. Stoner, Pulmonary oedema in rats given monocrotaline pyrrole. J Pathol, 1972. 106(4): P. 235-49
24. Hislop, A. and L. Reid, Arterial changes in Crotalaria spectabilis- induced pulmonary hypertension in rats. Br J Exp Pathol, 1974. 55(2): P. 153-63
25. Todorovich-Hunter, L., et al., Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis, 1992. 146(1): P. 213-23
26. Wilson, D.W., et al., Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol, 1992. 22(5-6): P. 307-25
27. Maruyama, K., et al., Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol, 1991. 261(6 Pt 2): P. H1716-26
28. Zhu, L., et al., The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest, 1994. 94(3): P. 1163-71
29. Ilkiw, R., et al., SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral arteries, suggesting a mechanism of monocrotaline-induced pulmonary hypertension in rats. Circ Res, 1989. 64(4): P. 814-25
30. Ye, C.L. and M. Rabinovitch, Inhibition of elastolysis by SC- 37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol, 1991. 261(4 Pt 2): P. H1255-67
31. Bieth, J.G., Mechanism of action of elastases., in Elastin and elastases. 1989, CRC Press Inc.: Boca Raton
32. Kobayashi, J., et al., Serum-induced vascular smooth muscle cell elastolytic activity through tyrosine kinase intracellular signalling. J Cell Physiol, 1994. 160(1): P. 121-31
33. Mohacsi, A., et al., [Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis]. Orv Hetil, 1996. 137(1): P. 15-21
34. Blann, A.D., et al., Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Eur J Vasc Endovasc Surg, 1996. 12(2): P. 218-22
35. Salvesen G, T.J., Properties of natural occuring leastase inhibitors., in Elastin and elastases. 1989, CRC Press Inc.: Boca Raton
36. Sallenave, J.M. and A. Silva, Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol, 1993. 8(4): P. 439-45
37. Robert, L., A.M. Robert, and B. Jacotot, Elastin-elastase-atherosclerosis revisited. Atherosclerosis, 1998. 140(2): P. 281-95
38. Rao, S.K., et al., Reduced capacity to inhibit elastase in abdominal aortic aneurysm. J Surg Res, 1999. 82(1): P. 24-7
39. Oho, S., et al., Increased elastin-degrading activity and neointimal formation in porcine aortic organ culture. Reduction of both features with a serine proteinase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(12): P. 2200-6
40. Oho, S. and M. Rabinovitch, Post-cardiac transplant arteriopathy in piglets is associated with fragmentation of elastin and increased activity of a serine elastase. Am J Pathol, 1994. 145(1): P. 202-10
41. Zaidi, S.H., et al., Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. J Clin Invest, 1999. 103(8): P. 1211-9
42. Zaidi, S.H., et al., Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. J Clin Invest, 2000. 105(12): P. 1687-95
43. O'Blenes, S.B., et al., Gene transfer of the serine elastase inhibitor elafin protects against vein graft degeneration. Circulation, 2000. 102(19 Suppl 3): P. III289-95
44. Thompson, K., et al., Endothelial and serum factors which include apolipoprotein A1 tether elastin to smooth muscle cells inducing serine elastase activity via tyrosine kinase-mediated transcription and translation. J Cell Physiol, 1998. 174(1): P. 78-89
45. Nuchprayoon, I., et al., PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol, 1994. 14(8): P. 5558-68
46. Wigle, D.A., et al., AML1-like transcription factor induces serine elastase activity in ovine pulmonary artery smooth muscle cells. Circ Res, 1998. 83(3): P. 252-63
47. Kuzuya, M. and A. Iguchi, Role of matrix metalloproteinases in vascular remodeling. JAtheroscler Thromb, 2003. 10(5): P. 275-82
48. Aimes, R.T. and J.P. Quigley, Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem, 1995. 270(11): P. 5872-6
49. Okada, Y., et al., Localization of matrix metalloproteinase 9 (92- kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: Implications for bone resorption. Lab Invest, 1995. 72(3): P. 311-22
50. Kahari, V.M. and U. Saarialho-Kere, Matrix metalloproteinases in skin. Exp Dermatol, 1997. 6(5): P. 199-213
51. Libby, P., Molecular bases of the acute coronary syndromes. Circulation, 1995. 91(11): P. 2844-50
52. Ross, R., The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature, 1993. 362(6423): P. 801-9
53. Dollery, C.M., J.R. McEwan, and A.M. Henney, Matrix metalloproteinases and cardiovascular disease. Circ Res, 1995. 77(5): P. 863-8
54. Celentano, D.C. and W.H. Frishman, Matrix metalloproteinases and coronary artery disease: A novel therapeutic target. J Clin Pharmacol, 1997. 37(11): P. 991-1000
55. Galis, Z.S., et al., Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 1994. 94(6): P. 2493-503
56. Knox, J.B., et al., Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation, 1997. 95(1): P. 205-12
57. Carmeliet, P., et al., Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet, 1997. 17(4): P. 439-44
58. Newman, K.M., et al., Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg, 1994. 20(5): P. 814-20
59. Patel, M.I., et al., Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg, 1996. 24(1): P. 82-92
60. Strauss, B.H., et al., Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res, 1994. 75(4): P. 650-8
61. Strauss, B.H., et al., In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res, 1996. 79(3): P. 541-50
62. Barolet, A.W., et al., Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler Thromb Vasc Biol, 2001. 21(8): P. 1269-74
63. Bendeck, M.P., et al., Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res, 1994. 75(3): P. 539-45
64. Zempo, N., et al., Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg, 1994. 20(2): P. 209-17
65. Tyagi, S.C., et al., Proteinases and restenosis in the human coronary artery: Extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis, 1995. 116(1): P. 43-57
66. Bendeck, M.P., C. Irvin, and M.A. Reidy, Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res, 1996. 78(1): P. 38-43
67. Zempo, N., et al., Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol, 1996. 16(1): P. 28-33
68. Thompson, K. and M. Rabinovitch, Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J Cell Physiol, 1996. 166(3): P. 495-505
69. Jones, P.L., K.N. Cowan, and M. Rabinovitch, Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol, 1997. 150(4): P. 1349-60
70. Jones, P.L. and M. Rabinovitch, Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res, 1996. 79(6): P. 1131-42
71. Jones, P.L., J. Crack, and M. Rabinovitch, Regulation of tenascin- C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol, 1997. 139(1): P. 279-93
72. Feng, Y., et al., Transcriptional profile of mechanically induced genes in human vascular smooth muscle cells. Circ Res, 1999. 85(12): P. 1118-23
73. Chung, C.Y., J.E. Murphy-Ullrich, and H.P. Erickson, Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell, 1996. 7(6): P. 883-92
74. Chung, C.Y. and H.P. Erickson, Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin- C. J Cell Biol, 1994. 126(2): P. 539-48
75. End, P., et al., Tenascin: A modulator of cell growth. Eur J Biochem, 1992. 209(3): P. 1041-51
76. Rabinovitch, M., Elastase and the pathobiology of unexplained pulmonary hypertension. Chest, 1998. 114(3 Suppl): P. 213S- 224S
77. Zhu, L., et al., A developmentally regulated program restricting insolubilization of elastin and formation of laminae in the fetal lamb ductus arteriosus. Lab Invest, 1993. 68(3): P. 321-31
78. Hinek, A., S. Molossi, and M. Rabinovitch, Functional interplay between interleukin-1 receptor and elastin binding protein regulates fibronectin production in coronary artery smooth muscle cells. Exp Cell Res, 1996. 225(1): P. 122-31
79. Cowan, B., et al., Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits afer heterotopic cardiac transplantation. J Clin Invest, 1996. 97(11): P. 2452-68
80. Yanagisawa, H., et al., Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature, 2002. 415(6868): P. 168-71
81. Nakamura, T., et al., Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature, 2002. 415(6868): P. 171-5
82. Nakamura, T., et al., DANCE, a novel secreted RGD protein expressed in developing, atherosclerotic, and balloon-injured arteries. J Biol Chem, 1999. 274(32): P. 22476-83
83. Kowal, R.C., et al., EVEC, a novel epidermal growth factor-like repeat-containing protein upregulated in embryonic and diseased adult vasculature. Circ Res, 1999. 84(10): P. 1166-76
84. Evan, G. and T. Littlewood, A matter of life and cell death. Science, 1998. 281(5381): P. 1317-22
85. Michel, J.B., Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol, 2003. 23(12): P. 2146-54
86. Ingber, D.E., Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res, 2002. 91(10): P. 877-87
87. Gartner, S. and H.S. Kaplan, Long-term culture of human bone marrow cells. Proc Natl Acad SciUS A, 1980. 77(8): P. 4756-9
88. Tzima, E., et al., Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. Embo J, 2001. 20(17): P. 4639-47
89. Howe, A.K., A.E. Aplin, and R.L. Juliano, Anchorage-dependent ERK signaling-mechanisms and consequences. Curr Opin Genet Dev, 2002. 12(1): P. 30-5
90. Han, D.K., et al., Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol, 1995. 147(2): P. 267-77
91. Isner, J.M., et al., Apoptosis in human atherosclerosis and restenosis. Circulation, 1995. 91(11): P. 2703-11
92. Kockx, M.M., et al., Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology, 1994. 25(4): P. 365-71
93. Clowes, A.W., M.A. Reidy, and M.M. Clowes, Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest, 1983. 49(3): P. 327-33
94. Perlman, H., et al., Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation, 1997. 95(4): P. 981-7
95. Kocher, O., et al., Cytoskeleton of rat aortic smooth muscle cells. Normal conditions and experimental intimal thickening. Lab Invest, 1984. 50(6): P. 645-52
96. Bochaton-Piallat, M.L., et al., Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol, 1995. 146(5): P. 1059-64
97. Flynn, P.D., et al., Thrombin generation by apoptotic vascular smooth muscle cells. Blood, 1997. 89(12): P. 4378-84
98. Bombeli, T., et al., Apoptotic vascular endothelial cells become procoagulant. Blood, 1997. 89(7): P. 2429-42
99. Bennett, M.R. and J.J. Boyle, Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis, 1998. 138(1): P. 3-9
100. Cowan, K.N., P.L. Jones, and M. Rabinovitch, Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res, 1999. 84(10): P. 1223-33
101. O'Blenes, S.B., et al., Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. J Thorac Cardiovasc Surg, 2001. 121(2): P. 279-89
102. Cowan, K.N., et al., Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med, 2000. 6(6): P. 698-702
103. Merklinger, S.L., et al., Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation, 2005. 112(3): P. 423-31
104. Campbell, A.I., et al., Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation, 2001. 104(18): P. 2242-8
105. Indolfi, C., et al., Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol, 2000. 35(1): P. 214-21
106. Nishimura, T., et al., Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003. 108(13): P. 1640-5
107. Laufs, U., V.L. Fata, and J.K. Liao, Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 1997. 272(50): P. 31725-9
108. Dimmeler, S., et al., HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest, 2001. 108(3): P. 391-7